• COLARIS AP®: Genetic Testing for Adenomatous Polyposis Colon Cancer Syndromes


COLARIS AP® detects mutations in the APC and MYH genes, which cause adenomatous polyposis colon cancer syndromes, including familial adenomatous polyposis (FAP), attenuated FAP (AFAP), and MYH-associated polyposis (MAP). The most common adenomatous polyposis conditions are thought to account for approximately 2% of all colon cancer.



COLARIS AP® is a simple blood test or oral rinse sample to find out if you have an APC or MYH mutation. Knowing the results may help you and your doctor act before cancer has a chance to develop.


  • Benefits of COLARIS AP®Testing


The results of the COLARIS AP®  test enable the development of a patient-specific medical management plan to significantly reduce the risk of cancer. COLARIS AP® helps to:

  • Target increased surveillance and other interventions specifically to individuals with  an APC or MYH gene mutation(s) maximizing patient care and increasing clinical efficiency
  • Improve patient compliance with tailored screening recommendations and preventive measures
  • Significantly improve outcomes and reduce medical costs through early diagnosis and treatment of cancer, should it develop
  • An individual’s risk for developing colorectal cancer can be reduced by nearly 100% with appropriate preventive measures in FAP.
  • Avoid unnecessary interventions for family members who do not test positive for the mutation(s) known to be in the family.
  • Counsel patients and their family members on the underlying cause of the cancer or adenomas
  • Avoid unnecessary interventions involving family members who do not test positive for the mutation(s) known to be in the family
  • Differentiate between AFAP, MAP, and Lynch syndrome
  • Medical Management and COLARIS AP*


It is possible to change the outcome for patients who have adenomatous polyposis syndromes. If a COLARIS AP® test result confirms the presence of adenomatous polyposis syndromes, the following medical management options may help reduce or even eliminate the risk of cancer.

  • Familial Adenomatous Polyposis (FAP)


  • Increased surveillance
  • Chemoprevention
  • Surgical management
  • Attenuated FAP (AFAP)


  • Increased surveillance
  • Surgical management
  • MYH-Associated Polyposis (MAP):


  • For patients who have MAP, medical society management recommendations include colonoscopies every 1-2 years starting at age 25-30, upper endoscopies every 3-5 years starting at age 30-35, and surgical considerations. The most appropriate medical management will vary based upon your patient’s clinical presentation.
  • For MYH mutation carriers (1 mutation), medical management should be determined by clinical findings and personal and family history of colorectal polyps and/or cancer. Current data are limited but suggest that any increase in risk, if present, is likely to be small.




For more information please contact us or visit or